

4,7-Dimethoxy-1,10-Phenanthroline: An Excellent Ligand for the Cu-Catalyzed *N*-Arylation of Imidazoles

Ryan A. Altman and Stephen L. Buchwald*

*Department of Chemistry
Massachusetts Institute of Technology
Cambridge, MA 02139*

sbuchwal@mit.edu

Supporting Information

Table of Contents:

| | |
|---|-----|
| General Considerations | S2 |
| Synthesis of 4,7-dimethoxy-1,10-phenanthroline | S3 |
| Experimental procedures for the <i>N</i> -arylation of imidazole with aryl iodides | S7 |
| Experimental procedures for the <i>N</i> -arylation of imidazole with aryl bromides | S13 |
| NMR Data | S18 |
| References | S32 |

General Considerations.


All reactions were carried out in resealable test tubes with teflon septa and run under a dry argon or nitrogen atmosphere. Copper (I) oxide (97%) was purchased from Aldrich company as a red powder. Anhydrous Cs_2CO_3 (99.9%) was purchased from Alfa Aesar; the bulk of the material was stored under nitrogen in a Vacuum Atmospheres glovebox. Small portions (~5 g) were removed from the glovebox in glass vials, stored in the air in a desiccator filled with anhydrous calcium sulfate, and weighed in the air. Poly(ethylene glycol) (M_n 3,400) was purchased from Aldrich. Generally, aryl halides and imidazoles were purchased from commercial sources and used without further purification. When necessary, aryl halides were filtered through neutral alumina, or distilled. Butyronitrile ($\geq 99\%$) was purchased from Aldrich and used without further purification. Anhydrous solvents were purchased from Aldrich in Sure-Seal® bottles. Flash column chromatography was performed with EM Science silica gel 60 (230-400 mesh). In all cases, dichloromethane was used to transfer the crude reaction material onto a silica gel column. A gradient elution technique was used for column chromatography, beginning with hexane and continuing to the specified concentration of ethyl acetate in hexane.

Yields reported in the publication are isolated (except where noted) and represent an average of at least two independent runs. Yields reported in the supporting information refer to a single experiment. Compounds described in the literature were characterized by comparing their ^1H NMR, and melting point (m.p.) to the previously reported data; their purity was confirmed by gas chromatographic analyses (GC). For known compounds prepared using the new method (conditions) described, a copy of the ^1H NMR spectrum, of each, is included. GC analyses were

performed on a Hewlett Packard 6890 instrument with an FID detector and a Hewlett Packard 10 m x 0.2 mm i.d. HP-1 capillary column using dodecane as an internal standard. Previously unknown compounds were synthesized, purified and analyzed from a single run and were then repeated to determine an average yield. They were characterized by ^1H NMR, ^{13}C NMR, m.p., and elemental analysis. Elemental analyses were performed by Atlantic Microlabs, Inc., Norcross, GA. For those compounds that did not give a satisfactory elemental analysis, a copy of their ^1H NMR spectrum is included. ^1H NMR and ^{13}C NMR were recorded on Varian 300 MHz and 500 MHz instruments with chemical shifts reported relative to the deuterated solvent or TMS. IR spectra were recorded on a Perkin-Elmer System 2000 FT-IR instrument for all previously unknown compounds (KBr disc). Melting points (uncorrected) were obtained on a Mel-Temp II capillary melting point apparatus.

Synthesis of 4,7-dimethoxy-1,10-phenanthroline (L).

The synthesis of **L** was adapted from literature precedent.¹ A larger scale preparation of **L** can be performed as follows. Alternatively, **2** can be purchased in gram quantities from commercial sources.

Scheme 1. Synthesis of 4,7-Dimethoxy-1,10-Phenanthroline

1,2-Bis-[(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidenemethyl)amino]benzene (**1**).

An oven-dried 2 L 2-neck flask equipped with a mechanical stirrer was charged with trimethyl orthoformate (850 mL, 7.8 mol) and Meldrum's acid (101 g, 0.700 mmol). The flask was fitted with a reflux condenser; the contents were flushed with N_2 and brought to a gentle reflux for 2 h. The resulting red solution was cooled ($\sim 80\text{ }^\circ\text{C}$) and phenylene diamine (32.4 g, 300 mmol) was added portionwise (*exothermic reaction*) resulting in the formation of a yellow solid. The mixture was heated to reflux, stirred vigorously for an additional hour and then cooled to room temperature. The resulting solid was filtered, washed with cold acetone (slightly soluble) and dried to afford 95 g (77%) of product as a flaky light-yellow solid. ^1H NMR (CDCl_3 , 400 MHz) δ 11.34 (br d, 2H), 8.50 (d, 2H), 7.41 (m, 4H, all ArH), 1.74 (s, 12H, Me). m.p. 208-210, decomp. (Lit. 209, decomp.).^{3a}

4,7-Dihydroxy-1,10-phenanthroline (2**).** A 5 L 3-neck flask equipped with a mechanical stirrer and a *large air-cooled* reflux condensor was charged with 3 L of diphenyl ether and was heated to $240\text{ }^\circ\text{C}$ using a heating mantle. During the addition of **1**, the flask was open to atmospheric

pressure under a stream of N₂. Precursor **1** was added in small portions resulting in vigorous gas evolution (**Caution**). When the addition was complete, the mixture was brought to reflux (260 °C) for 30 min. The mixture was allowed to cool to 80 °C, and the precipitate was isolated by vacuum filtration and washed with acetone until the filtrate was colorless. The product was further washed with excess hexane and diethyl ether. Drying by vacuum filtration, then under hi-vac at 60 °C, afforded 41.5 g (86%) of a fine dark-brown powder. Although the title compound was essentially insoluble in common NMR solvents, a spectrum could be obtained using NaOH in D₂O. ¹H NMR (D₂O, NaOH, 400 MHz) δ 8.17 (d, 2H, *J* = 5.6 Hz), 7.75 (s, 2H), 6.43 (d, 2H *J* = 5.6 Hz). Anal Calc. for C₁₂H₈N₂: C 67.92, H 3.80. Found: C 67.60, H 3.59. m.p. stable up to 250 °C (Lit. 471-474, decomp.).²

4,7-Dichloro-1,10-phenanthroline (3). A 1 L 2-neck round bottom flask equipped with a stir bar, reflux condenser, and distillation apparatus was flame-dried and allowed to cool under an atmosphere of N₂. Phosphorous oxychloride (400 mL) and **2** (20.0 g, 94.3 mmol) were added to the flask under a N₂ purge. The apparatus was immersed in an oil bath and heated at reflux for 2 h (the condenser for the distillation apparatus was not filled with water at this time). After this period, the circulation of water for the distillation apparatus was turned on and roughly half of the excess phosphorous oxychloride was removed by gentle vacuum distillation. The solution was cooled to room temperature and crushed ice was slowly added to the reaction mixture (**Caution: very exothermic!**) while keeping the temperature between 10 and 30 °C with an ice bath. When HCl gas evolution ceased, the acidic solution was stirred for one hour at room temperature to dissolve the black solids that formed. The resulting dark cloudy solution was filtered through activated charcoal (Darco®) to give a translucent-beige solution, which was

brought to pH 13 by the slow addition of 20% KOH solution while maintaining the temperature below 25 °C. The white precipitate that formed was collected by suction filtration, washed with excess H₂O, and dried under vacuum overnight at 60 °C affording **3** as a white solid. The product was used in the subsequent step without further purification. ¹H NMR (DMSO, 400 MHz) δ 9.09 (d, 2H, *J* = 4.8 Hz), 8.41 (s, 2H), 8.08 (d, 2H, *J* = 4.8 Hz). m.p. 245-247 (Lit. 249-250).^{3c}


4,7-Dimethoxy-1,10-phenanthroline (L). An oven-dried 3-neck round bottom flask was cooled under a stream of nitrogen. Anhydrous methanol (1.2 L) was added, and purged with N₂ for 10 min. Sodium metal (9.20 g, 400 mmol) was slowly added in small pieces while the solution was stirred. A reflux condenser was attached, and **3** (all that was produced in the previous step) was added. The flask was heated to reflux for 24 hours under an atmosphere of N₂. Concentration of the resulting solution to ~30 mL and addition of cold water (250 mL) resulted in the precipitation of a tan solid. The flask was stored overnight in a refrigerator to allow complete precipitation of the solid. The product was collected by filtration, washed with excess water, and dried under vacuum overnight at 60 °C affording 16.7 g (74 % over 2 steps) of a tan solid, which can be recrystallized from benzene. ¹H NMR (CDCl₃, 300 MHz) δ 8.93 (d, 2H, *J* = 5.3 Hz), 8.18 (s, 2H), 7.03 (d, 2H, *J* = 5.3 Hz), 4.09 (s, 6H). m.p. 210-212 (Lit. 209-210).^{3e}

General procedure for the *N*-arylation of imidazoles with aryl iodides.

An oven-dried screw-cap test tube was charged with Cu₂O (0.025 mmol), **L** (0.075 mmol), imidazole (1.2 mmol), aryl iodide (1.00 mmol, if solid), poly(ethylene glycol) (200 mg), Cs₂CO₃ (1.4 mmol), and a magnetic stir bar. The reaction vessel was fitted with a rubber septum. The vessel was evacuated and back-filled with argon or nitrogen, and this sequence was repeated an


additional time. Aryl iodide (1.00 mmol, if liquid) and solvent (0.5 mL) were then added successively. The reaction tube was sealed, and stirred in a pre-heated oil bath for the designated time period. The reaction mixture was cooled to room temperature, diluted with dichloromethane (10 mL), and filtered through a plug of celite, eluting with additional dichloromethane (50 mL). The filtrate was concentrated and the resulting residue was purified by flash chromatography to provide the desired product.

Experimental procedures for the *N*-arylation of imidazole with aryl iodides.




1-Phenyl-1*H*-imidazole

The general procedure was followed using Cu₂O (3.6 mg, 0.025 mmol), **L** (18 mg, 0.075 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), iodobenzene (112 μL, 1.00 mmol), and imidazole (82 mg, 1.2 mmol), with NMP (0.5 mL) as solvent for 3 h at 110 °C. Chromatographic purification (hexane / ethyl acetate 1 : 3) afforded 1-phenyl-1*H*-imidazole (slightly yellow oil, 131 mg, 92 %). The low catalyst loading experiment was preformed using the general procedure with Cu₂O (0.4 mg, 0.0025 mmol), **L** (1.8 mg, 0.0075 mmol), PEG (2.0 g), Cs₂CO₃ (4.50 g, 14 mmol), iodobenzene (1.12 mL, 10 mmol), and imidazole (820 mg, 12 mmol), in butyronitrile (2.0 mL) as solvent for 48 h at 110 °C. Chromatographic purification (hexane / ethyl acetate 1 : 3) provided 1-phenyl-1*H*-imidazole (slightly yellow oil, 1.34 g, 93 %). ¹H NMR (300 MHz, CDCl₃) δ 7.82 (s, 1H), 7.47-7.41 (m, 2H), 7.36-7.29 (m, 3H), 7.25 (bs, 1H), 7.18 (bs, 1H).³ A copy of the ¹H NMR spectrum is provided.




3-Imidazol-1-yl-benzonitrile

The general procedure was followed using Cu₂O (3.6 mg, 0.025 mmol), **L** (18 mg, 0.075 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), 3-iodobenzonitrile (229 mg, 1.00 mmol), and imidazole (82 mg, 1.2 mmol), with butyronitrile (0.5 mL) as solvent for 24 h at 90 °C. Chromatographic purification (hexane / ethyl acetate 1 : 3) 3-imidazol-1-yl-benzonitrile (white needles, 158 mg, 94 %). ¹H NMR (500 MHz, CDCl₃) δ 7.89 (s, 1H), 7.71-7.60 (m, 4H), 7.30 (bs, 1H), 7.25 (bs, 1H). m.p. 151-154 °C (Lit. 156-157 °C).⁴ A copy of the ¹H NMR spectrum is provided.




1-(3-Nitro-phenyl)-1H-imidazole

The general procedure was followed using Cu₂O (3.6 mg, 0.025 mmol), **L** (18 mg, 0.075 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), 3-nitroiodobenzene (249 mg, 1.00 mmol), and imidazole (83 mg, 1.2 mmol) with acetonitrile (0.5 mL) as solvent for 29 h at 80 °C. Chromatographic purification (hexane / ethyl acetate 1 : 3) 1-(3-nitro-phenyl)-1H-imidazole (white solid, 177 mg, 93 %). ¹H NMR (500 MHz, CDCl₃) δ 8.25 (t, 1H, *J* = 1.9), 8.19 (ddd, 1H, *J* = 1.1, 1.9, 7.9 Hz), 7.94 (s, 1H), 7.75 (ddd, 1H, *J* = 1.4, 2.2, 8.1 Hz), 7.69 (t, 1H, *J* = 8.0 Hz), 7.36 (s, 1H), 7.23 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 149.1, 138.3, 125.5, 131.5, 131.2, 126.9, 122.1, 118.0, 116.2. m.p. 109-110 °C (Lit. 109-110 °C).⁵ A copy of the ¹H NMR spectrum is provided.




4-Imidazol-1-yl-benzoic acid ethyl ester

The general procedure was followed using Cu₂O (3.6 mg, 0.025 mmol), **L** (18 mg, 0.075 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), ethyl-4-iodobenzoate (168 μ L, 1.00 mmol), and imidazole (82 mg, 1.2 mmol), 3 Å molecular sieves (200 mg, powdered, flame activated) with acetonitrile (0.5 mL) as solvent for 23 h at 80 °C. Chromatographic purification (hexane / ethyl acetate 1 : 3) 4-imidazol-1-yl-benzoic acid ethyl ester (white crystals, 184 mg, 84 %). ¹H NMR (500 MHz, CDCl₃) δ 8.18 (td, 2H, *J* = 1.8, 8.5 Hz), 7.96 (s, 1H), 7.48 (td, 2H, *J* = 1.8, 8.8), 7.37 (s, 1H), 7.26 (s, 1H), 4.43 (q, 2H, *J* = 7.1 Hz), 1.44 (t, 3H, *J* = 7.0 Hz). m.p. 101-103 °C (Lit. 100-102 °C).⁶ A copy of the ¹H NMR spectrum is provided.




1-(4-Bromo-phenyl)-1*H*-imidazole⁷

The general procedure was followed using Cu₂O (3.6 mg, 0.025 mmol), **L** (18 mg, 0.075 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), 1-bromo-4-iodobenzene (340 mg, 1.20 mmol), and imidazole (68 mg, 1.0 mmol) with butyronitrile (0.5 mL) as solvent for 24 h at 90 °C. Chromatographic purification (hexane / ethyl acetate 1 : 1) provided 1-(4-bromo-phenyl)-1*H*-imidazole (white crystals, 171 mg, 78 %). ¹H NMR (300 MHz, CDCl₃) δ 7.83 (bs, 1H), 7.63 (m, 2H), 7.32-7.20 (m, 4H). m.p. 120-122 °C. GC/MS of the crude material showed an 6.1 : 1 mixture of 1-(4-bromo-phenyl)-1*H*-imidazole to 1-(4-iodo-phenyl)-1*H*-imidazole. A copy of the ¹H NMR spectrum is provided.




1-(3,5-Dichloro-phenyl)-2-methyl-1*H*-imidazole

The general procedure was followed using Cu₂O (7.2 mg, 0.05 mmol), **L** (36 mg, 0.15 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), 1,3-dichloro-5-iodobenzene (273 mg, 1.00 mmol), 2-methylimidazole (100 mg, 1.2 mmol) with butyronitrile (0.5 mL) as solvent for 24 h at 110 °C. Chromatographic purification (hexane / ethyl acetate 1 : 3) provided 1-(3,5-dichloro-phenyl)-2-methyl-1*H*-imidazole (white needles, 194 mg, 86 %). ¹H NMR (300 MHz, CDCl₃) δ 7.44 (t, 1H, *J* = 1.8), 7.23 (d, 2H, *J* = 1.9), 7.05 (d, 1H, *J* = 1.2), 6.99, (d, 1H, *J* = 1.2), 2.40 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 139.8, 135.8, 128.5, 128.4, 124.1, 14.0. IR (KBr disc, cm⁻¹) 1534, 1501, 1463, 1451, 1405, 1305, 1176, 1143, 1115, 1099, 985, 850, 781. Anal. Calc. for C₁₀H₈N₂Cl₂: C 52.89, H 3.55. Found: C 52.95, H 3.44. m.p. 122-125 °C.




1-(2-Isopropyl-phenyl)-1*H*-imidazole

The general procedure was followed using Cu₂O (3.6 mg, 0.025 mmol), **L** (18 mg, 0.075 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), 2-isopropyl iodobenzene (246 mg, 1.00 mmol), and imidazole (82 mg, 1.2 mmol) with butyronitrile (0.5 mL) as solvent for 48 h at 110 °C. Chromatographic purification (hexane / ethyl acetate 1 : 1) provided 1-(2-isopropyl-phenyl)-1*H*-imidazole (white crystals, 171 mg, 92 %). ¹H NMR (300 MHz, CDCl₃) δ 7.57 (bs, 1H), 7.46-7.42 (m, 2H), 7.31-7.11 (m, 3H), 7.05 (m, bs), 2.74 (heptet, 1H, *J* = 6.9 Hz), 1.16 (d, 6H, *J* = 6.9 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 145.0, 135.1, 129.4, 129.2, 127.0, 126.7, 126.4, 121.1, 27.4, 24.0. m.p. 76-77 °C (Lit. 67-68 °C).⁸ Anal. Calc. for C₁₂H₁₄N₂: C 77.38, H 7.58. Found: C 77.42, H 7.78. A copy of the ¹H NMR spectrum is provided.




(2-Imidazol-1-yl-phenyl)-methanol

The general procedure was followed using Cu_2O (3.6 mg, 0.025 mmol), **L** (18 mg, 0.075 mmol), PEG (200 mg), Cs_2CO_3 (0.45 g, 1.4 mmol), 2-iodobenzylalcohol (234 mg, 1.00 mmol), and imidazole (82 mg, 1.2 mmol) with butyronitrile (0.3 mL) as solvent for 24 h at 110 °C. Chromatographic purification (hexane / ethyl acetate 1 : 1) provided (2-imidazol-1-yl-phenyl)-methanol (clear crystals, 165 mg, 95 %). ^1H NMR (300 MHz, CDCl_3) δ 7.62 (dd, 2H, $J = 1.7, 7.6$ Hz), 7.45 (td, 1H, $J = 1.4, 7.5$ Hz), 7.38 (td, 1H, $J = 1.4, 7.4$ Hz), 7.23 (dd, 1H, $J = 1.1, 7.7$ Hz), 7.13 (s, 1H), 7.08 (s, 1H), 4.90 (bs, 1H), 4.46 (s, 1H). m.p. 102-104 °C (Lit. 100.5-102.5 °C).⁹ A copy of the ^1H NMR spectrum is provided.




1-Biphenyl-2-yl-1H-imidazole

The general procedure was followed using Cu_2O (7.2 mg, 0.05 mmol), **L** (36 mg, 0.15 mmol), PEG (200 mg), Cs_2CO_3 (0.45 g, 1.4 mmol), 2-iodobiphenyl (176 μL , 1.00 mmol), and imidazole (82 mg, 1.2 mmol) with butyronitrile (0.6 mL) as solvent for 72 h at 120 °C. Chromatographic purification (hexane / ethyl acetate 1 : 1) provided 1-biphenyl-2-yl-1H-imidazole (slightly yellow crystals, 179 mg, 81 %). ^1H NMR (300 MHz, CDCl_3) δ 7.50-7.33 (m, 5H), 7.30-7.24 (m, 3H), 7.02 (bs, 1H), 6.82 (bs, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 137.8, 137.5, 135.2, 131.5, 128.7, 128.7, 128.6, 128.3, 127.8, 126.3. Anal. Calc. for $\text{C}_{15}\text{H}_{12}\text{N}_2$: C 81.79, H 5.49. Found: C 81.50, H 5.46. m.p. 93-95 °C.



1-Naphthalen-1-yl-1H-imidazole

The general procedure was followed using Cu₂O (7.2 mg, 0.05 mmol), **L** (36 mg, 0.15 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), 1-iodonaphthalene (146 μ L, 1.00 mmol), and imidazole (82 mg, 1.2 mmol) with NMP (0.3 mL) as solvent for 24 h at 110 °C. The crude reaction mixture was dissolved in 20 mL of water, and extracted with dichloromethane (5 x 30 mL). The combined organic layers were dried with MgSO₄, and the solvent was removed *in vacuo*. Chromatographic purification (hexane / ethyl acetate 1 : 1) provided 1-naphthalen-1-yl-1H-imidazole (yellow-white solid, 179 mg, 92 %). ¹H NMR (300 MHz, CDCl₃) δ 7.94-7.92 (m, 2H), 7.76, (bs, 1H), 7.61-7.48 (m, 4 H), 7.43 (d, 1H, *J* = 7.0 Hz), 7.30 (bs, 1H), 7.25 (bs, 1H). m.p. 63-64 °C (Lit. 62 °C).¹⁰ A copy of the ¹H NMR spectrum is provided.



1-(4-Fluoro-phenyl)-2-phenyl-1H-imidazole


The general procedure was followed using Cu₂O (3.6 mg, 0.025 mmol), **L** (18 mg, 0.075 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), 4-fluoriodobenzene (222 mg, 1.00 mmol), 2-phenylimidazole (173 mg, 1.2 mmol) with butyronitrile (0.3 mL) as solvent for 24 h at 110 °C. Chromatographic purification (hexane / ethyl acetate 3 : 1) provided 1-(4-fluoro-phenyl)-2-phenyl-1H-imidazole (white solid, 211 mg, 89 %). ¹H NMR (300 MHz, CDCl₃) δ 7.36-7.30 (m, 2H), 7.24-7.16 (m, 4H), 7.15-7.09 (m, 2H), 7.06 (s, 1H), 7.03-6.96 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 163.5, 160.2, 134.5, 129.0, 128.5, 128.4, 128.2, 127.6, 127.5, 116.5, 116.2. IR (KBr disc, cm⁻¹) 1509, 1501, 1466, 1414, 1303, 1285, 1233, 1212, 1151, 1128, 1091, 1068, 970, 915, 840, 775,

747, 715, 697. Anal. Calc. for $C_{15}H_{11}N_2F$: C 75.62, H 4.65. Found: C 75.39, H 4.62. m.p. 111-114 °C.

General procedure for the *N*-arylation of imidazoles with aryl bromides.

An oven-dried screw-cap test tube was charged with Cu_2O (0.05 mmol), **L** (0.15 mmol), imidazole (1.2 mmol), aryl bromide (1.00 mmol, if solid), poly(ethylene glycol) (200 mg), Cs_2CO_3 (1.4 mmol), and a magnetic stir bar. The reaction vessel was fitted with a rubber septum. The vessel was evacuated and back-filled with argon or nitrogen, and this sequence was repeated an additional time. Aryl bromide (1.00 mmol, if liquid), and solvent (0.5 mL) were then added successively. The reaction tube was sealed, immersed, and stirred in a preheated oil bath for the designated time period. The reaction mixture was cooled to room temperature, diluted with dichloromethane (10 mL), filtered through a plug of celite, and eluted with additional dichloromethane (50 mL). The filtrate was concentrated and the resulting residue was purified by flash chromatography to provide the desired product.


Experimental procedures for the *N*-arylation of imidazole with aryl bromides.



4-Imidazol-1-yl-phenol


The general procedure was followed using Cu_2O (7.2 mg, 0.05 mmol), **L** (36 mg, 0.15 mmol), PEG (400 mg), Cs_2CO_3 (1.0 g, 3.0 mmol), 4-bromophenol (172 mg, 1.00 mmol), and imidazole (82 mg, 1.2 mmol) with butyronitrile (0.5 mL) as solvent for 15 h at 110 °C. After cooling to ambient temperature, the crude reaction mixture was dissolved in 20 mL 2M $HCl_{(aq)}$, and washed once with diethyl ether. The aqueous layer was brought to pH 8 with Na_2CO_3 , and extracted repeatedly with CH_2Cl_2 . The combined organic layers were dried with anhydrous $MgSO_4$, and concentrated.

Chromatographic purification (1 % ethanol in ethyl acetate, dry pack) afforded 4-imidazol-1-yl-phenol (white crystals, 198 mg, 90 %). ^1H NMR (300 MHz, CD_3OD) δ 7.95 (bs, 1H), 7.41 (bs, 1H), 7.35-7.30 (m, 2H), 7.01 (bs, 1H), 6.92-6.87 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 158.7, 130.8, 129.8, 124.3, 117.4, 24.0. m.p. 196-198 °C (Lit. 188-190 °C [203-205 °C MeOH, H_2O]).¹¹ A copy of the ^1H NMR spectrum is provided.



3-Imidazol-1-yl-phenylamine


The general procedure was followed using Cu_2O (7.2 mg, 0.05 mmol), **L** (36 mg, 0.15 mmol), PEG (200 mg), Cs_2CO_3 (0.45 g, 1.4 mmol), 3-bromoaniline (109 μL , 1.00 mmol), and imidazole (82 mg, 1.2 mmol) with butyronitrile (0.25 mL) as solvent for 20 h at 110 °C. Chromatographic purification (ethyl acetate) afforded 3-imidazol-1-yl-phenylamine (white powder, 141 mg, 88 %). ^1H NMR (300 MHz, CDCl_3) δ 7.79 (bs, 1H), 7.21-7.15 (m, 3H), 6.72-6.68 (m, 1H), 6.64-6.60 (m, 2H). 4.01 (bs, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 148.2, 138.4, 135.6, 130.7, 130.1, 118.4, 114.0, 111.1, 107.7. m.p. 112-114 °C (Lit. 111-113 °C).¹² A copy of the ^1H NMR spectrum is provided.



1-(4-Imidazol-1-yl-phenyl)-ethanone


The general procedure was followed using Cu_2O (7.2 mg, 0.05 mmol), **L** (36 mg, 0.15 mmol), PEG (200 mg), Cs_2CO_3 (0.45 g, 1.4 mmol), 4-bromoacetophenone (199 mg, 1.00 mmol), and imidazole (82 mg, 1.2 mmol) with butyronitrile (0.4 mL) as solvent for 48 h at 110 °C. Chromatographic

purification (hexane / ethyl acetate 1 : 3) afforded 1-(4-imidazol-1-yl-phenyl)-ethanone (white solid, 159 mg, 86 %). ^1H NMR (300 MHz, CDCl_3) δ 8.04, (m, 2H), 7.92 (bs, 1H), 7.46 (m, 2H), 7.33 (bs, 1H), 7.19 (bs, 1H), 2.59 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 196.6, 140.7, 135.7, 135.4, 131.2, 130.4, 120.7, 117.8, 26.7. m.p. 112-114 °C (Lit. 110-112 °C).¹³ A copy of the ^1H NMR spectrum is provided.



1,4-*bis*(Imidazol-1-yl)-benzene¹⁴


The general procedure was followed using Cu_2O (7.2 mg, 0.05 mmol), **L** (36 mg, 0.15 mmol), Cs_2CO_3 (0.90 g, 2.8 mmol), 1,4-dibromobenzene (236 mg, 1.00 mmol), and imidazole (164 mg, 2.4 mmol) with NMP (0.5 mL) as solvent for 30 h at 110 °C. The crude reaction mixture was diluted in excess CH_2Cl_2 , and filtered through a celite plug. After removal of the solvent *in vacuo*, the product was crystallized from EtOAc and stored in a freezer overnight, to afford 1,4-*bis*(imidazol-1-yl)-benzene (white solid, 200 mg, 95 %). ^1H NMR (500 MHz, CDCl_3) δ 7.90 (bs, 2H), 7.54 (s, 4H), 7.32 (bs, 1H), 7.26 (bs, 1H). m.p. 190 °C (decomp.). IR (KBr disc, cm^{-1}) 1534, 1485, 1304, 1248, 1105, 1059. Anal Calc. for $\text{C}_{12}\text{H}_{10}\text{N}_4$: C 68.56, H 4.79. Found C 68.49, H 4.90.



1,2-Diphenyl-1*H*-imidazole


The general procedure was followed using Cu_2O (14.4 mg, 0.10 mmol), **L** (72 mg, 0.30 mmol), PEG (200 mg), Cs_2CO_3 (0.45 g, 1.4 mmol), 4-*t*-butylbromobenzene (173 μL , 1.00 mmol), and imidazole (82 mg, 1.2 mmol) with butyronitrile (0.6 mL) as solvent for 72 h at 120 °C.

Chromatographic purification (hexane / ethyl acetate 1 : 1) afforded 1,2-diphenyl-1*H*-imidazole (white crystals, 198 mg, 90 %). ¹H NMR (300 MHz, CDCl₃) δ 7.42-7.32 (m, 5H), 7.28-7.16 (m, 6H), 7.14 (d, 1H, *J* = 1.1 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 138.6, 130.4, 129.5, 129.1, 128.6, 128.4, 128.2, 128.2, 125.9, 123.0. m.p. 88-89 °C (Lit. 90 °C).¹⁵ A copy of the ¹H NMR spectrum is provided.



1-(4-*tert*-Butyl-phenyl)-2-methyl-1*H*-imidazole

The general procedure was followed using Cu₂O (7.2 mg, 0.05 mmol), **L** (36 mg, 0.15 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), 4-*t*-butylbromobenzene (173 μL, 1.00 mmol), 2-methylimidazole (100 mg, 1.2 mmol) with butyronitrile (0.25 mL) as solvent for 48 h at 110 °C. Chromatographic purification (hexane / ethyl acetate 1 : 3) afforded 1-(4-*tert*-butyl-phenyl)-2-methyl-1*H*-imidazole (yellow oil, 207 mg, 97 %). ¹H NMR (300 MHz, CDCl₃) δ 7.41 (m, 2H), 7.12 (m, 1H), 6.94 (bs, 1H), 6.91 (bs, 1H), 2.28 (s, 3H), 1.29 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 151.1, 135.3, 127.5, 126.3, 124.9, 12.7, 34.6, 31.3, 13.8. IR (KBr Disc, cm⁻¹) 2962, 2870, 1608, 1579, 1513, 1463, 1419, 1365, 1302, 1269, 1178, 1139, 1114, 996, 986, 842, 730, 674, 571. A copy of the ¹H NMR spectrum is provided.



1-*ortho*-Tolyl-1*H*-imidazole

The general procedure was followed using Cu₂O (7.2 mg, 0.05 mmol), **L** (36 mg, 0.15 mmol), PEG (200 mg), Cs₂CO₃ (0.45 g, 1.4 mmol), 2-bromotoluene (120 μL, 1.00 mmol), and imidazole (82



mg, 1.2 mmol) with butyronitrile (0.3 mL) as solvent for 28 h at 110 °C. Chromatographic purification (hexane / ethyl acetate 1 : 1) afforded 1-*ortho*-tolyl-1*H*-imidazole (yellow oil, 140 mg, 89 %). ¹H NMR (300 MHz, CDCl₃) δ 7.59 (bs, 1H), 7.37-7.28 (m, 3H), 7.23-7.20 (m, 2H), 7.06 (bs, 1H), 2.19 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 148.2, 138.4, 135.6, 130.7, 130.1, 118.4, 114.0, 111.1, 107.7.¹⁶ A copy of the ¹H NMR spectrum is provided.

STANDARD PHOTON PARAMETERS

```

exp2  szpu1
SAMPLE
date   Oct 3 2005   dfrq   DEC. 8 UT
solvent CDCl3      dn      125.785
file   ACQUISITION exp   dpr   37
sfrq   500.235     dn      nmh
in      2.280      dm      18000
at      2.280      dm      18000
np      24000      dseq
bv      10000.0    dres   1.0
bv      not used   homo   PROCESSING
ss      1          wtf11a
tdmr    59         proc   ft
pw      9.8        fm      131072
d1      0          math
nt      1498.2     warr
ct      16         wexp
clock   16         wbs
gain    not used   wnt
13      FLAOS      n
1n      n
dp      y
hs      nm
DISPLAY
tp      -923.8
wp      10000.0
vs      151
vc      0
wc      250
hzam    40.00
ls      100.00
rf1     4638.5
rfp     3636.7
th      1.000
ins
re      ph

```




RAA III 157

STANDARD PROTON PARAMETERS

```

expt 12001
SAMPLE
date Dec 1 2005 11:00 DEC. & VT
solvent CDCl3 125.674
file ACQUISITION exp C13
1498.1
freq 149.749
in 149.749
nt 3.277
np 65536
sw 9988.8
fu not used
bs 16
lpr 56
pw 8.2
d1 1498.1
nt 16
clock 16
gain not used
FLAG$
11 n
dp y
hs n
sp -1004.8
vp 9988.8
vc 151
hz 250
ls 40.00
rf1 182.79
rfp 1004.8
ins cdc ph
nm 1.000

```





STANDARD PROTON PARAMETERS

```

exp1 52pu1
SAMPLE
date Nov 20 2005
solvent CDC13
file C13
ACQUISITION
sfreq 300.136
in 3.277
at 3.277
np 4096
pb 4096
fb 4096
ls 4096
tpwr 56
pw 8.2
d1 0
tof 1498.1
nt 16
ct 16
clock not used
galt not used
flags 1.0
il 1
in 1
dp 1
hs 1
DISPLAY
sp -1004.5
wp 9998.3
vs 151
vc 250
hzmm 40.00
ls 816.35
rf1 4637.5
rfp 3633.1
th 1.000
ins 1.000
nm cdc ph
DEC. & VE
125.674
34
1498.1
10000
1.0
DEC2
DEC3
0
1
0
n
c
200
1.0
DEC3
0
1
0
n
c
200
1.0
PROCESSING
n
ft
5536
f

```






STANDARD PHOTON PARAMETERS

exp1 s2mu1



SAMPLE
date Oct 1 2005 ifrq DEC. & VT 125.674
solvent CDC13 dn C13
file ACQUISITION exp 34
sfreq 499.749 do 1498.1
tn W1 dm 10000
at 3.257 dm
wv 6527 dm
fb 9988 dm
bs not used homo 1.0
tpur 16
pw 56 dfrq2 DEC2
d1 8.2 dn2
lof 1498.1 dfr2 1
nt 16 dn2 n
ct 16 dms2 C
a1ock n dfr2 280
gain not used
l1 FLAGS n homo2 1.0
dn V dfrq3 0
hs DISPLAY nhs dfr3 1
sp -1004.5 dfr3 0
vp 9988.0 dn3 n
vs 131 dms3 C
tc 250 dfr3 200
b2am 48.0 dfr3 1.0
ls 182.78 homo2
rfi 4637.8 PROCESSING n
rfp 3633.1 wfile
th 2.000 f
ms cdc ph 85538 f

WERR
WERRP
WERR
WERR





[illegible]

expl s2pu1

[illegible]

exp2 s2pul



| date | sample | DEC. & VI |
|--------------|----------|--------------|
| Oct 3 2005 | | dfrq 125.795 |
| solvent | CACLS | dn 33 |
| file | exp | dprw 10809 |
| ACQUISITION | exp | dof 1.0 |
| strq 500.235 | da | nmn |
| in H2 | dam | c |
| at nt | dnf | |
| 3.204 | dscq | |
| 64000 | drea | |
| 10000.0 | dras | |
| SW | not used | homo |
| ns | 8 | PROCESSING |
| ss | 8 | 1 vfile |
| tpwr | 30 | proc |
| FW | 5.8 | proc |
| dl | 0 | math |
| toft | 1499.2 | 16 warr |
| nt | 16 | wexp |
| atlock | not used | n wbs |
| gain | not used | wnt |
| flags | n | |
| il | n | |
| in | n | |
| dn | y | |
| hs | min | |
| DISPLAY | | |
| sp | -447.8 | |
| amp | 6530.8 | |
| vt | 251 | |
| sc | 8 | |
| nc | 269 | |
| ncrm | 26.12 | |
| zfm | 100.00 | |
| fl | 400.00 | |
| ff | 3836.7 | |
| th | 1.008 | |
| ins | ph | |



Ryan Alteman 1-m-naphthalene

0802 stullh

SAMPLE DEC 8 2004 DEC. 8 VT
 date Dec 8 2004 dfrq 300.100
 solvent CDCl3 dn H1
 file /data/export/~dpar 30
 host/sbuck/dra/mw dcf 0
 host/tra-1-m-naph- de nm
 holend.fid den c
 ACQUISITION der 200
 sfrq 300.100 wrlle
 n 1.915
 us 17880 pfc not used
 sw 4508.5
 fs not used werr
 bs 16 wesp
 tper 54 wbs
 pw 7.0 wnt
 d1 1.000
 tof 0
 nt 16
 ct 16
 dlock n
 gain not used
 FLAGB n
 l1 n
 l2 n
 dp DISPLAY y
 sp -718.8
 up 4508.3
 vs 104
 sc 250
 vpc 18.03
 r1 500.00
 r11 2898.8
 r1a 2181.7
 th 20
 ins cdc pH
 nm 1.000







STANDARD PROTON PARAMETERS

exp1 12pul

SAMPLE
date Nov 20 2005 DEC. 8 VT
solvent Nov CDC13 dn 125.874
file exp 34
ACQUISITION
sfreq 499.749 dn 1498.1
tn 11 dm 10000
at 3.277 dmf
sp 65536 dseq
pa 5938.0 dres
fb not used hmo 1.0
bc 16 hmo2 DEC2
pw 56 dfrq2 0
d1 8.2 dn2 1
tof 1498.1 ddf2 0
nt 16 dm2 n
ct 16 dm2 c
atock n dm2 200
gain not used dseq2
FLAG dres2 1.0
l1 n hmo2 DEC3
in n dfrq3 0
dp y dn3
hs DISPLAY
sp -1006.0 dpr3 1
wp 5998.0 ddf3 0
vs 151 dm3 n
vc 151 dm3 c
hz 250 ddf3 200
hzmax 40 dm3 1.0
rs 33.52 ddf3
rf1 4639.1 hmo3
rfp 3633.1 wfile n
th proc ft
ms 1.000 f 65536
na cdc ph math
userf
userp
wls
wnt





STANDARD PROTON PARAMETERS


```

exp1 32pul
SAMPLE
date Nov 20 2005 DEC. & VI
solvent CDCl3 d1h 125.674
file C13
ACQUISITION exp d1h 34
sfrq 499.749 d1h 1498.1
ln h1 dnm 10000
at 3.277 dnmf
sp 45556 dnmf
wa 99328 dnmf
td not used hnmf 1.0
bs 16 hnmf DEC2
ls 56 d1h2 0
pw 8.2 d1h2 1
d1 0 d1h2 1
lof 1498.1 d1h2 0
nt 16 d1h2 n
ct 16 d1h2 C
clock n d1h2 200
gain not used d1h2 1.0
FLAGS n hnmf2 DEC3
l1 n
ln y d1h3 0
da n
hs nm d1h3 1
DISPLAY nm d1h3 0
sp -1005.1 d1h3 0
wp 99328.0 d1h3 n
vt 151 d1h3 C
vc 250 d1h3 200
hzam 46.80 d1h3 1.0
is 816.95 hnmf3
rfi 4638.2
rff 3623.1 wifile
th 7
ins 1.000 f1
nm cdc ph 1.000 f1
math 65536
VERT
WEXP
WDS
UNT

```



I207





exp5 stdlib


| | | |
|-------------|-------------|--------------|
| SAMPLE | | DEC. & VT |
| date | Feb 26 2005 | dfrq 300.100 |
| solute | CDC13 | dn |
| solvent | | upwr 30 |
| exp | | nof 0 |
| ACQUISITION | | dm min |
| frrq | 300.100 | c 200 |
| at | 1.985 | |
| rt | 17.88 | |
| ms | 4500 | |
| sw | 4500 | wflls |
| fb | not used | proc fl |
| bz | | fn not used |
| tour | 50 | |
| pw | 7.0 | mstr |
| d1 | 1.000 | uswp |
| tof | 0 | bls |
| nt | 15 | vhl |
| ct | 0 | |
| a1ock | n | |
| gain | not used | |
| FLAGS | | |
| l1 | n | |
| in | n | |
| dp | y | |
| DISPLAY | | |
| sp | -717.1 | |
| up | 4506.3 | |
| r2 | 151 | |
| uc | 0 | |
| azm | 250 | |
| bzmm | 18.03 | |
| rs | 500.00 | |
| rfl | 2889.1 | |
| rffp | 2181.7 | |
| lh | 20 | |
| ins | 9.000 | |
| cdc | ph | |



```

exp1 stdhl
SAMPLE
data      Jul 22 2005
solvent   CbCl3
file       exp1
ACQUISITION
srfreq    500.100
in         H1
at         1.995
cp         17884
pw         4500.5
wf         not used
fb         4
bn         50
t2wr       7.0
p1w        1.000
d1         0
t1f        0
nt         16
ct         16
n1         0
n1lock     not used
gain       1
in         n
in1         n
in2         n
in3         y
DISPLAY
sp         -156.8
wp         20033.7
vs         151
sc         0
bc         250
f2nm       11.53
f1nm       378.09
f1f1       701.10
f1f2       22
in1nm      1.006
in2nm      250
in3nm      550
DEC. & VT
dfrq       300.100
dn         11
dpr         30
dar         0
dat         nm
proc        20 C
wfile       PROCSSING
fn          not used

```



-
- ¹ The synthesis of **1**, **2**, **3** and **L** were performed according to a combination of the following procedures. (a) Graf, I. G.; Jastreiter, D.; da Silva, L. E.; Rebelo, R. A.; Montalban, A. G.; McKillop, A. *Tetrahedron* **2002**, 58, 9095. (b) Schmittel, M.; Ammon, H. *Eur. J. Org. Chem.* **1998**, 785. (c) Snyder, H. R.; Freier, H. E. *J. Am. Chem. Soc.* **1946**, 68, 1320. d) Wehman, P.; Kaasjager, de Lange, W. G.; Jartl, F.; Kamer, P. C. J.; van Leeuwen, P. W. N. M. *Organometallics* **1995**, 14, 3751. (e) Zacharias, D. E.; Case, F. H. *J. Am. Chem. Soc.* **1962**, 27, 3878-3882.
- ² Molock, F. F. *J. Heterocyclic Chemistry* **1983**, 20, 681.
- ³ Sezen, B.; Sames, D. *J. Am. Chem. Soc.* **2003**, 125, 5274-5275.
- ⁴ Wang, L.; Chen, Z. C. *J. Chem. Res. Synop.* **2000**, 8, 367-369.
- ⁵ Khan; Polya. *J. Chem. Soc. C* **1970**, 85-88.
- ⁶ Artico, M.; Silvestri, R.; Stefancich, G.; Avigliano, L.; Di Giulio, A. *Eur. J. Med. Chem. Chim. Ther.* **1992**, 27, 219-228.
- ⁷ Wang, Li; Chen, Zhen-Chu. *J. Chem. Res. Synop.* **2000**, 8, 367 - 369.
- ⁸ Du Pont de Nemours, E. I., and Co. "1-(Alkyl-Substituted Phenyl)Imidazoles Useful in ACTH Reserve Assay." US 3637731. 1972.
- ⁹ Du Pont de Nemours, E. I., and Co. "1-Substituted Imidazoles Useful in ACTH [Adrenocorticotrophin] Reserve Assay." US 3541109. 1970.
- ¹⁰ Perry, M. C.; Cui, X.; Powell, M. T.; Hou, D. R.; Reibenspies, J. H.; Burgess, K. *J. Am. Chem. Soc.* **2003**, 125, 113-123.
- ¹¹ Tashiro, M.; Itoh, T.; Fukata, G. *Synthesis* **1982**, 217-219.
- ¹² Paul, R.; Hallett, W. A.; Hanifin, J. W.; Reich, M. F.; Johnson, B. D. *J. Med. Chem.* **1993**, 36, 2716-2725.
- ¹³ Liu, J.; Chen, J.; Zhao, J.; Zhao, Y.; Li, L.; Zhang, H. *Synthesis* **2003**, 2661-2666.
- ¹⁴ Pozharskii et al. *Chem. Heterocycl. Compd.* **1970**, 6, 194-197.
- ¹⁵ Sezen, B.; Sames, D. *J. Am. Chem. Soc.* **2003**, 125, 10580-10585.
- ¹⁶ Collman, J. P.; Zhong, M.; Zeng, L.; Costanzo, S. *J. Org. Chem.* **2001**, 66, 1528-1531.